NASDAQ:SLS
SELLAS Life Sciences Group Inc. Stock News
$1.40
+0.0500 (+3.70%)
At Close: May 24, 2024
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
12:47pm, Wednesday, 10'th Jan 2024
The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.
- Phase 2a Enrollment Completed in 45 mg Safety Cohort: Median Overall Survival (OS) Not Reached; 89% of Patients Alive with Significant Antileukemic Effect Observed in 87.5% of Evaluable Patients -
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
09:01am, Thursday, 04'th Jan 2024
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
Why Is Sellas Life Sciences (SLS) Stock Down 25% Today?
08:41am, Thursday, 04'th Jan 2024
Sellas Life Sciences (NASDAQ: SLS ) stock is taking a beating on Thursday after the late-stage clinical biopharmaceutical company announced a proposed public share offering. Sellas Life Sciences has
SELLAS Life Sciences Announces Proposed Public Offering
08:05pm, Wednesday, 03'rd Jan 2024
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing no
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
07:30am, Wednesday, 03'rd Jan 2024
- Company to Host Corporate Update Webinar Today, January 3, 2024, at 8:30 am ET- -Interim Analysis of Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia Expected in First Q
SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
08:45am, Tuesday, 17'th Oct 2023
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference
04:19pm, Monday, 18'th Sep 2023
NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
08:30am, Tuesday, 13'th Jun 2023
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme
SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
05:05pm, Thursday, 25'th May 2023
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
Sellas Life Sciences raises $20 million from public offering of stock, warrants
08:42am, Friday, 24'th Feb 2023
Sellas Life Sciences Group Inc. SLS, -3.40% said Friday that it raised $20.0 million, through the public sale of common shares and warrants to buy stock. Shares of the biopharmaceutical company, which
Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?
08:29am, Friday, 24'th Feb 2023
SELLAS Life Sciences (NASDAQ: SLS ) stock is falling on Friday after the late-stage clinical biopharmaceutical company announced a proposed public offering. According to a press release, SELLAS Life S
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
08:30am, Wednesday, 02'nd Nov 2022
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme
Solaris and Government of Ecuador Announce Investment Protection Agreement for Warintza Project, Securing Stability of Regulations and Tax Incentives to Accelerate Development
08:05pm, Thursday, 09'th Jun 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, June 09, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or “the Company”) is pleased to announce an agreement with the Gover
